Related Experiment Video
Updated: Sep 13, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
MicroRNA regulation of PPARG Signalling: Therapeutic implications for pulmonary hypertension
Renzhi Su1, Armalya Pritazahra1, ShirinC C Saverimuttu1
1Institute of Cardiovascular Science, University College London, Rayne Building, 5 University Street, London, WC1E 6JF, UK.
Abstract:
Gene Ontology (GO) is a tool which provides functional gene annotations and is an essential resource for knowledge discovery and the analysis of biological datasets. Although considerable research has quantified the functional similarity between gene products and physiological processes, their contribution to human pathophysiology requires further exploration. Previous studies have identified PPARG participating in multiple signalling pathways, particularly those networks involving TGFB1 and BMP2 in pulmonary arterial smooth muscle cells (PASMCs) and their role in pulmonary arterial hypertension (PAH) pathobiology. To enhance the description of PPARG in the GO resource, we systematically curated the proteins it interacts with and its physiological role in human cells and tissues. In addition, we curated the microRNAs that may play a role in PAH through their regulation of PPARG expression and downstream impact on cellular processes. We curated using robust experimental criteria 101 human miRNAs that regulate the expression of 17 PPARG signalling pathway-relevant proteins. Of these, 91 of our curated miRNAs were previously unannotated in terms of directly regulating the expression of these priority proteins. By submitting these annotations to the GO Consortium database, we have significantly enhanced the breadth and depth of the GO description of PPARG-associated signalling pathways relevant to the pulmonary vasculature.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
MicroRNAs
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...